findings suggest that gold compounds will continue to be a mainstay first-line disease-modifying agent in the treatment of rheumatoid arthritis but that there may be less reluctance to use other agents as physicians become increasingly familiar and comfortable with alternative options , especially penicillamine and immunosuppressive agents .
C0003873
rheumatoid
C0030817
penicillamine